USE OF SINGLE SAMPLE CLEARANCE ESTIMATES OF CYTOCHROME-P450 SUBSTRATES TO CHARACTERIZE HUMAN HEPATIC CYP STATUS INVIVO

被引:46
作者
BACHMANN, KA [1 ]
JAUREGUI, L [1 ]
机构
[1] ST VINCENTS MED CTR, TOLEDO, OH 43606 USA
关键词
D O I
10.3109/00498259309059384
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
1, Single sample clearance estimates (CL/F) of orally administered ethosuximide were obtained in four groups of healthy adult subjects. One group was treated with phenobarbital to induce CYP2B/2C and CYP3A activity; one group was treated with rifampin to induce CYP3A activity; one group consisted of cigarette smokers (increased CYP1A activity), and one group was untreated (controls). Ethosuximide CL/F values were slightly, though not significantly, increased among cigarette smokers (12.5% increase) and the phenobarbital group (25% increase), but rifampin treatment resulted in a significant increase (65%). 2. The influence of rifampin treatment on the single sample oral clearances of antipyrine, theophylline, phenytoin, carbamazepine, ethosuximide, quinidine, valproic acid, and lorazepam was investigated to determine whether rifampin induces only CYP3A. Rifampin treatment significantly increased the oral clearance of each drug from 1-4-fold (valproic acid) to 3-4-fold (quinidine). These findings indicate that the inductive effect of rifampin extends well beyond CYP3A.
引用
收藏
页码:307 / 315
页数:9
相关论文
共 33 条
[1]  
BACHMANN K, 1986, INT J CLIN PHARM TH, V24, P546
[2]   INVIVO EVIDENCE THAT ETHOSUXIMIDE IS A SUBSTRATE FOR CYTOCHROME-P450IIIA [J].
BACHMANN, K ;
CHU, CA ;
GREEAR, V .
PHARMACOLOGY, 1992, 45 (03) :121-128
[3]   THE USE OF SINGLE SAMPLE CLEARANCE ESTIMATES TO PROBE HEPATIC DRUG-METABOLISM - HANDPRINTING THE INFLUENCE OF CIGARETTE-SMOKING ON HUMAN HEPATIC DRUG-METABOLISM [J].
BACHMANN, KA ;
NUNLEE, M ;
MARTIN, M ;
SCHWARTZ, J ;
JAUREGUI, L ;
FORNEY, RB .
XENOBIOTICA, 1990, 20 (05) :537-547
[4]   THE USE OF SINGLE SAMPLE CLEARANCE ESTIMATES TO PROBE HEPATIC DRUG-METABOLISM - HANDPRINTING THE INFLUENCE OF PHENOBARBITONE ON HUMAN HEPATIC DRUG-METABOLISM [J].
BACHMANN, KA ;
NUNLEE, M ;
MARTIN, M ;
JAREGUI, L .
XENOBIOTICA, 1991, 21 (10) :1385-1392
[5]   UPDATE ON RIFAMPIN DRUG-INTERACTIONS .2. [J].
BORCHERDING, SM ;
BACIEWICZ, AM ;
SELF, TH .
ARCHIVES OF INTERNAL MEDICINE, 1992, 152 (04) :711-716
[6]   MECHANISM-BASED INVIVO INACTIVATION OF LAURIC ACID HYDROXYLASES [J].
CAJACOB, CA ;
DEMONTELLANO, PRO .
BIOCHEMISTRY, 1986, 25 (16) :4705-4711
[7]  
CAMPBELL ME, 1987, DRUG METAB DISPOS, V15, P237
[8]  
DAUJAT M, 1991, METHOD ENZYMOL, V206, P345
[9]   RELATIONSHIP BETWEEN PHENYTOIN AND TOLBUTAMIDE HYDROXYLATIONS IN HUMAN LIVER-MICROSOMES [J].
DOECKE, CJ ;
VERONESE, ME ;
POND, SM ;
MINERS, JO ;
BIRKETT, DJ ;
SANSOM, LN ;
MCMANUS, ME .
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 1991, 31 (02) :125-130
[10]   BIOTRANSFORMATION OF CAFFEINE AND THEOPHYLLINE IN MAMMALIAN-CELL LINES GENETICALLY ENGINEERED FOR EXPRESSION OF SINGLE CYTOCHROME-P450 ISOFORMS [J].
FUHR, U ;
DOEHMER, J ;
BATTULA, N ;
WOLFEL, C ;
KUDLA, C ;
KEITA, Y ;
STAIB, AH .
BIOCHEMICAL PHARMACOLOGY, 1992, 43 (02) :225-235